Edwards’ Heart Monitor Wins FDA Approval

Edwards Lifesciences Corp. said Tuesday it has received clearance from the Food and Drug Administration to begin marketing its latest monitoring system, which provides a picture of blood circulation in a patient’s heart.

The Irvine maker of products to treat cardiovascular disease said in a press release that its Vigilance CCO/SvO2/CEDV Monitor gives gives clinicians a complete picture using a single system.

Such hemodynamic monitoring data help clinicians make more rapid decisions when treating patients in hospital emergency rooms and surgical and critical care settings, Edwards said.